|
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
|
Completed
|
BI 10773
|
3
|
1245.25
|
King Fahad Medical City (Riyadh)
|
|
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
|
Completed
|
Bevacizumab
|
3
|
MO22923
|
King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam)
|
|
Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS
|
Completed
|
Dantrolene
|
2
|
EGL-4104-C-1502
|
King Fahad Medical City (Riyadh)
|
|
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
|
Completed
|
Sebelipase alfa (SBC-102)
|
2
|
LAL-CL03
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
|
Completed
|
ITCA 650
|
3
|
ITCA 650-CLP-105
|
King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)_ Imam Abdulrahman Al Faisal Hospital NG (Dammam)_ King Fahad Medical City (Riyadh)
|
|
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
|
Completed
|
Travoprost 0.004% / Timolol
|
3
|
C-12-008
|
King Khaled Eye Specialist Hospital (Riyadh)
|
|
"Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection"
|
Completed
|
TMC435 (simeprevir) / Pegylated interferon alfa-2a (PegIFNα-2a) / Ribavirin (RBV)
|
3b
|
TMC435HPC3014
|
King Faisal Specialist Hospital and Research Center (Riyadh)_ King Abdulaziz Medical City NG (Riyadh)_ King Khalid University Hospital (Riyadh)
|
|
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled
|
Completed
|
Lantus® / Glimepiride / human insulin [NPH]
|
3
|
LANTU_C_02762
|
King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah)
|
|
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP).
|
Completed
|
Asfotase Alfa
|
2
|
ENB-010-10
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients
|
Completed
|
Innohep (Tinzaparin) / Warfarin
|
3
|
IN 0901 INT
|
King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
|
